Article Versions Notes

Murakami K, Sasaki Y, Asahiyama M, Yano W, Takizawa T, Kamiya W, Matsumura Y, Anai M, Osawa T, Fruchart J-C, et al. Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. Cells. 2022; 11(4):720. https://doi.org/10.3390/cells11040720

Murakami, Kentaro, Yusuke Sasaki, Masato Asahiyama, Wataru Yano, Toshiaki Takizawa, Wakana Kamiya, Yoshihiro Matsumura, Motonobu Anai, Tsuyoshi Osawa, Jean-Charles Fruchart, and et al. 2022. "Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis" Cells 11, no. 4: 720. https://doi.org/10.3390/cells11040720

Murakami, K., Sasaki, Y., Asahiyama, M., Yano, W., Takizawa, T., Kamiya, W., Matsumura, Y., Anai, M., Osawa, T., Fruchart, J.-C., Fruchart-Najib, J., Aburatani, H., Sakai, J., Kodama, T., & Tanaka, T. (2022). Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. Cells, 11(4), 720. https://doi.org/10.3390/cells11040720